It’s quite interesting to observe that the new CERN’s product, this new anti-estrogen, we will say, they are confirming their superiority in a very particular niche. Thus, this is the endocrine-sensitive metastatic breast cancer population with harboring an ESR1 mutation. And they are proving to be superior to any other endocrine therapy, single agent or in combination with other therapies...
It’s quite interesting to observe that the new CERN’s product, this new anti-estrogen, we will say, they are confirming their superiority in a very particular niche. Thus, this is the endocrine-sensitive metastatic breast cancer population with harboring an ESR1 mutation. And they are proving to be superior to any other endocrine therapy, single agent or in combination with other therapies. But the question is around how effective could these drugs be in terms of superiority to standard treatment in a naive or more earlier population. And particularly, the question about EMPRESS is if giredestrant, that is one of these new estrogen receptor downregulators, can be superior to tamoxifen in a way that it could also preclude us from thinking that for some patients we could even avoid ovarian suppression. I think that this is the major objective in the early future regarding these drugs. We could start to think that some patients will not require or require less duration of ovarian suppression function. That is probably a very dramatic treatment for many, many young patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
